<DOC>
	<DOC>NCT02847637</DOC>
	<brief_summary>This is a randomized, multicenter, open-label, Phase 3 clinical study in participants aged 12 years or older to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in participants with severe hemophilia A without inhibitors against FVIII.</brief_summary>
	<brief_title>A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Body weight &gt;=40 kilogram (kg) at the time of screening Diagnosis of severe congenital hemophilia A Documentation of the details of prophylactic or episodic FVIII treatment and of number of bleeding episodes for at least the last 24 weeks Adequate hematologic function Adequate hepatic function Adequate renal function For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of &lt;1% per year during the treatment period and for at least 5 elimination halflives (24 weeks) after the last dose of study drug Inherited or acquired bleeding disorder other than hemophilia A Previous or current treatment for thromboembolic disease or signs of thromboembolic disease Conditions that may increase risk of bleeding or thrombosis History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection Known human immunodeficiency virus (HIV) infection with CD4 count &lt;200 cells/mcL within 24 weeks prior to screening. Participants with HIV infection who has CD4 &gt;200 and meet all other criteria are eligible Use of systemic immunomodulators at enrollment or planned use during the study, with the exception of antiretroviral therapy Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose additional risk, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study Planned surgery (excluding minor procedures) during the study Receipt of emicizumab in a prior investigational study; an investigational drug to treat or reduce the risk of hemophilic bleeds within 5 halflives of last drug administration; a nonhemophiliarelated investigational drug concurrently, within last 30 days or 5 halflives, whichever is shorter Pregnant or lactating, or intending to become pregnant during the study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Emicizumab</keyword>
</DOC>